Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × Safety Issues × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1682 Carcinoma, Non-Small-Cell Lung 1190 Prostatic Neoplasms 896 Colorectal Neoplasms 753 Multiple Myeloma 659 Leukemia, Myeloid, Acute 633 Lung Neoplasms 612 Neoplasms 607 Neoplasm Metastasis 565 Lymphoma 518 Pancreatic Neoplasms 507 Carcinoma, Hepatocellular 502 Stomach Neoplasms 468 Leukemia 458 Recurrence 444 Leukemia, Lymphocytic, Chronic, B-Cell 403 Melanoma 402 Precursor Cell Lymphoblastic Leukemia-Lymphoma 392 Ovarian Neoplasms 389 Lymphoma, Non-Hodgkin 387 Myelodysplastic Syndromes 372 Lymphoma, Large B-Cell, Diffuse 367 Brain Neoplasms 366 Squamous Cell Carcinoma of Head and Neck 364 Head and Neck Neoplasms 356 Rectal Neoplasms 344 Glioblastoma 340 Hodgkin Disease 305 Carcinoma, Renal Cell 303 Esophageal Neoplasms 299

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03620435 2018-08-13

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 2 Unknown

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon ⚡